Ernexa Therapeutics Inc.

ERNA Healthcare Biotechnology

Ernexa Therapeutics Inc.’s revenue for fiscal 2024 (year ended December 2024) was $582,000.00, up 755.9% from fiscal 2023. In the quarter to June 2026, revenue fell 94.1%, EPS grew 77.7% and free cash flow fell 64.1%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

2.09 0.08 −3.69%
Market cap
$3.5M
P/E
0.0×
Fwd P/E
−0.5×
Dividend yield
—
F-score
n/a
Altman Z
−70.69
Beneish M
−24.48
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

87.78% (687.80%) (2,514.66%) (321.22%)
ROA
(264.31%) (253.99%) (146.19%) (176.62%)
ROIC
(1,185.59%) (1,126.57%) 0.00% 0.00%
Return on Tangible Assets
(1,383.27%) (12,368.42%) (172.08%) (403.22%)
Average Days of Receivables
0.00 0.00 — 0.00
Free Cash Flow per Share
(29.50) (28.03) (9.16) (7.50)
Free Cash Flow
(9.70) (7.07) (7.25) (8.88)
Other line items

Show all line items

Columns are period end dates